Navigation Links
Cephalon Announces Strong Third Quarter Financial Results
Date:11/8/2007

re, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.

This press release and/or the financial results attached to this press release include "Adjusted Net Income," "Basic Adjusted Income per Common Share," "Basic Adjusted Income per Common Share Guidance," and "Diluted Adjusted Income Per Common Share," amounts that are considered "non-GAAP financial measures" under SEC rules. As required, we have provided reconciliations of these measures. Additional required information is located in the Form 8-K furnished to the SEC in connection with this press release.

CEPHALON, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2007 2006 2007 2006

REVENUES:

Sales $428,729 $470,513 $1,287,802 $1,246,825

Other revenues 9,692 11,820 34,865 32,562

438,421 482,333 1,322,667 1,279,387

COSTS AND EXPENSES:

Cost of sales 82,258 83,160 251,970 250,613

Research and development 93,527 86,439 274,078 294,899

Selling, general and

administrative 186,456 161,108 527,962 470,158

Settlement reserve 369,000 - 425,000 -

Impairment charge - - - 12,417

731,241 330,707 1,479,010 1,028,087

INCOME (LOSS) FROM OPERATIONS (292,820) 15
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... Virginia (PRWEB) June 03, 2015 Photo-Eyewear™ ... changed its name to PogoTec™, Inc. ( http://www.PogoTec.com ... its electronic wearable device products and technologies it is ... creation of three business divisions, PogoTec™ will provide focused ... devices as follows: , , On-Track™ ...
(Date:6/3/2015)... 2015 The National Center for ... record by scaling CD-adapco’s flagship simulation tool STAR-CCM+® ... , STAR-CCM+ is a comprehensive multidisciplinary engineering ... innovation and lower product development costs. CD-adapco joined ... manufacturer Cray to push the code to new ...
(Date:6/3/2015)... June 03, 2015 Global Stem ... Inc. have announced plans to conduct Romania’s first ever ... Through an alliance with Miami-based Stem Cell Training, Inc., ... the Adipose and Bone Marrow Stem Cell Training Course ... reconstructive plastic surgery specialist practicing in Bucharest and Tel ...
(Date:6/3/2015)... June 03, 2015 Intelligent Implant ... of US Patent No. 9,044,273, underpinning the Revolution™ ... thoraco-lumbar spinal fusion implant procedure by eliminating complicated ... one easy-to-use disposable instrument tray. The implants, designed ... benefits over previous technology. Intelligent Implant Systems has ...
Breaking Biology Technology:Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 2Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 3NCSA Scales CD-adapco’s STAR-CCM+ to New World Record of 102,000 Cores on Blue Waters 2NCSA Scales CD-adapco’s STAR-CCM+ to New World Record of 102,000 Cores on Blue Waters 3Global Stem Cells Group Announces First Stem Cell Training Course to Take Place in Romania 2Global Stem Cells Group Announces First Stem Cell Training Course to Take Place in Romania 3Intelligent Implant Systems Announces US Patent Attained for Revolution™ Spinal System 2
... CANNES, France, June 24, 2011 Mediabrands, IPG ... Cannes Lions International Advertising Festival, the results of ... by MIT, Affectiva is able to record and ... points, correlating to an individual,s facial features are ...
... June 24, 2011 Amgen (NASDAQ: AMGN ... for Human Use (CHMP) of the European Medicines Agency ... (panitumumab) be approved for use in the European Union ... second-line in combination with FOLFIRI in patients who have ...
... ,   Coventry Building ... Legion by launching Poppy Online,Saver , a market-leading ... Saver is an ,easy access internet savings account ... each year, with,further withdrawals possible with the loss of ...
Cached Biology Technology:The IPG Media Lab and Affectiva Announce Winners of First Annual Neuromarketing Awards 2The IPG Media Lab and Affectiva Announce Winners of First Annual Neuromarketing Awards 3Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 2Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 3Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 4Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 5Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 6Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 7Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 8Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 9Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 10Coventry Launches Market Leading Online Savings Account With Added Poppy Appeal 2Coventry Launches Market Leading Online Savings Account With Added Poppy Appeal 3
(Date:5/28/2015)... May 28, 2015 Industry analyst firm ... new report titled "Markets for Self-Healing Materials: 2015-2022." According ... capsule and vascular systems, biomaterials, relevant shape memory ... around $2.7 billion by 2020. The ... coverage of smart materials. Other recent n-tech reports have ...
(Date:5/25/2015)... , May 25, 2015  Australia,s market for wearable ... although 2014 saw the advent of several trials and ... April 2015 is expected to ignite interest in wearables ... Australia . This in turn will ... and drive new partnerships amongst vendors and distributors. ...
(Date:5/21/2015)... 2015 According to a ... (Hardware, Software, Services), by Applications (Surveillance (Airborne, Maritime, ... End-Users (Military & Defense & Commercial) - Global ... Market is expected to grow from $7252.0 Million ... a Compound Annual Growth Rate (CAGR) of 6.6%. ...
Breaking Biology News(10 mins):The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4
... highly efficient techniques, Carnegie and Colombian scientists have ... locked in tropical vegetation for 40% of the ... area about four times the size of Switzerland. ... stocks at high spatial resolution over large areas ...
... July 25, 2012 - Migraine can be a disabling ... the acupoint PC6 Neiguan, an approach to controlling nausea ... by published clinical studies in medical literature for the ... May 2012 Neurological Sciences (journal of the ...
... regulated process that occurs in all animals and plants as ... New research published in BioMed Central,s open access journal ... physiological events in the lace plant ( Aponogeton madagascariensis ) ... its leaves. The aquatic lace plant, endemic to ...
Cached Biology News:Forest carbon monitoring breakthrough in Colombia 2Forest carbon monitoring breakthrough in Colombia 3Published clinical trial demonstrates efficacy of Sea-Band® for migraine-related nausea 2Lace plants explain programmed cell death 2